When: Sustained break of $526 (200 SMA) on volume >4M shares

Then: Exit position - stop loss triggered

When: Daily close above $601.77 (52-week high) on volume >5M with RSI expansion

Then: Shift toward Overweight rating

When: Sustained breakdown below $526 on volume >4M

Then: Shift to Underweight with 30-35% trim

HOLD - do not add until $520-540; reduce exposure 25-33% if price breaks $546 on volume; trim into strength at $595-605

• Q2 2026 results strong but already priced in: Revenue +12% currency-neutral, operating margin 61.7%, EPS +21.8% on a stock that rallied ~25% off June lows into the print
• Technical setup is late-stage extended: MACD histogram compressed 64% (5.39 to 1.94), tested upper Bollinger Band at $583.71 on August 3, ATR expanded 19% ($10.5 to $12.49), stock +10.6% above 50 SMA and +8.5% above 200 SMA
• Golden cross not yet formed: 50 SMA still below 200 SMA, anchoring on a lagging indicator that confirms mature trends near exhaustion
• Buyback EPS inflation understated: organic EPS growth overstated by 3-4 percentage points when buybacks are stripped out; at higher prices, buybacks retire fewer shares per dollar deployed
• Valuation stretched asymmetrically: PEG of 1.76, trailing P/E 31x, forward P/E 24.9x on $22.97 consensus; downside risk to multiple compression exceeds upside to prior highs
• Macro margin of safety absent: 10% recession probability with stock at all-time-high-adjacent valuations; Fed hawkish pivot or labor market weakness would hit MA on multiple compression plus earnings pressure
• Competitive landscape heating up: Visa BioCatch acquisition signals AI fraud competition intensifying; BVNK integration risk and stablecoin revenue model unclear
• Traders recommendation is disciplined HOLD, not bearish: explicit $520-540 add target, $546 reduce signal, $595-605 trim zone protects against asymmetric downside while maintaining structural thesis exposure

→ vs aggressive: Q2 fundamentals celebrated today are already priced in after 25% rally into the earnings event; marginal buyer at $571 is not compensated for the risk taken

→ vs aggressive: Bearish divergence dismissal is intellectually dishonest; MACD histogram compression of 64% is not noise and signals momentum regime losing steam, not pre-confirmation of bullish breakout

→ vs aggressive: Buyback efficiency argument confuses absolute dollars with per-share efficiency; mechanical EPS inflation masks materially weaker underlying earnings trajectory

→ vs aggressive: Forward P/E 24.9x at 31x trailing is only compelling if consensus estimates prove correct; upside to prior highs is 10-15% while downside from multiple compression is asymmetric and significant

→ vs aggressive: Treating 10% recession probability as negligible ignores that stock at all-time-highs with no margin of safety creates two-vector downside on macro disappointment

→ vs aggressive: Competitive threats dismissed too quickly; Visa BioCatch acquisition and BVNK integration risk warrant acknowledgment even if not existential near-term

→ vs aggressive: Conflating HOLD with add-at-current-levels is a strawman; the trader explicitly advocates maintaining benchmark weight while protecting against late-stage extended entry

HOLD at benchmark weight with tiered add framework; do not add at $571

• Operating margin at 61.7%, operating cash flow at $17.65 billion, $11.73 billion in buybacks fully funded
• MACD histogram compression of 64% from 5.39 to 1.94 over one month while price grinds sideways is momentum regime losing steam
• Stock at upper Bollinger band after tagging $583.71; 31x trailing earnings valuation
• Q2 EPS growth of 21.8% includes 3-4 percentage point share count reduction tailwind from buybacks
• Golden cross (50 over 200) is a lagging confirmation, not a leading buy signal
• Base case: 89% no-cut, 10% recession probability; supports benchmark weight
• Asymmetric scenario: benign case 5-15% upside next quarter; hawkish surprise (hot CPI, Fed hold) causes 10-20% drawdown from multiple compression toward 25x earnings
• BVNK acquisition positions MA on offense in tokenization; Visa's BioCatch deal raises AI-fraud competitive bar
• Tiered add framework: 25% incremental size on pullback to 10 EMA at $561 with stop below $552; 75% incremental size on pullback to $546-$526 zone
• Trim 15-25% of position into $595-$605 zone as rebalance, not directional reduce
• Risk management: reduce trigger should be sustained break of 200 SMA at $526 on volume > 4 million shares

→ vs aggressive: Dismissal of MACD histogram compression is 'technically lazy'—a 64% compression from 5.39 to 1.94 at upper Bollinger band is textbook late-stage momentum pattern, not pre-confirmation of breakout

→ vs aggressive: Buyback argument ignores per-share efficiency—absolute buyback dollars accelerating matters less than fewer shares retired per dollar deployed at 31x earnings

→ vs aggressive: Golden cross is lagging confirmation that often occurs near exhaustion points, not a leading buy signal to add at current levels

→ vs conservative: 'Already in the price' argument cuts both ways and provides no actionable forward guidance

→ vs conservative: $520-$540 buy zone anchored to 50 SMA (currently $516) which is below 200 SMA ($526), making it the structurally weaker level—more probable support is $526-$546

→ vs conservative: $546 reduce trigger is mid-Bollinger band that often produces false breakdowns and would have investors selling into support ($526) rather than buying it

→ vs conservative: Overweights 10% recession tail risk when base case supports holding quality at benchmark weight

→ vs conservative: Underweights secular tailwinds: BVNK acquisition, Open USD consortium, value-added services acceleration, cross-border recovery